Monogram Technologies (NASDAQ:MGRM) reported 1st quarter 2024 results on May 14th which were largely in line with expectations. Research and development expenses for the quarter ending March 31 ...

Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products ...

Monogram received FDA 510(k) clearance for its robotic-assisted total knee arthroplasty system, Monogram mBôs TKA. The company plans initial placements with key surgeons and aims to expand its ...